Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Underwater?..lol..I was given up for dead...I am a long ways underwater still but I have never lost belief in the company...
I did sell off a block of 50 thousand shares for a significant loss about 3 months ago to free up some trading capital and have done quite well trading an assortment of canadian mj startups...so I have made back about half of what I lost when i sold some of my OW.
The company needs to follow through on promises and move us forward.
The trading today reminds us of February 2017 in terms of how quickly the stock can move.
Difference is today is based on science and reality..Feb 2017 was mj hype and criminal activity by JF/ZIV
BOOOOM...just printed .1788
Nothing wrong with flipping OWCP for small profits...
Congrats!..
I did the same with a cannabis player (Yield Growth Corp) on the CSE here in Canada..bought 8990 shares at .22 on Monday and sold today for .30...an easy 700..lol
I could have sold at .35 on Wednesday.... but held till today.
What did the pr say?
This is ridiculous..seriously.
That's not JP Morgan.
RAMAT GAN, Israel, Dec. 27, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today that management will attend Biotech Showcase 2019 to be held in San Francisco, CA on January 7-9, 2019.
Mordechai Bignitz, Chief Executive Officer, and Yossi Dagan, Chief Financial Officer, will be conducting face-to-face meetings with investors and others at Biotech Showcase. Please send a request through the conference partnering portal or by contacting Stephanie Carrington at stephanie.carrington@icrinc.com or 646-277-1282.
It bothers me that OWCP is not listed as an attendee at the conference on their website as of yet.
Same to you Smallville...all the best in 2019!
Having gone through this process before myself, it depends on how the application is written and applied for. Sometimes a patent application can be given for the EU for example and then list the countries that are included...Other times it goes this way where individual countries are granted first. I would suspect there is a good reason this Czech patent has been granted alone.
Could it be there will be some manufacturing taking place in the Czech republic?
Otherwise why not get a blanket grant for all of the EU?
More to this imo.
All the best to the true OWCP longs for 2019!
Happy New Year.
There is absolutely no relevance to your claim that a reverse split is coming for OWCP.
You made one post a week ago saying the same thing.
Post facts not bs.
And we're no where near that..so why is it even relevant...it isn't .
Just more bs fear mongering...
lol..a rs on a stock with 148 million os...
Only in your world
One of your informed posts....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133949115
Viaderma...one of the biggest scams going...yet you come here and slam OWCP....
...calling out HorizenBull...ya right...lol
FSD Pharma Responds to Therapix Termination of Binding LOI
December 21, 2018 04:12 PM Eastern Standard Time
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) in response to Therapix Biosciences’ termination of the company’s binding letter of intent (LOI) to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement:
“It is important to note that our efforts to gain full US exchange listing are advancing as planned. We are also in active and positive conversations with potential strategic and investment partners across the globe”
Tweet this
“While we are disappointed that Therapix Biosciences has given notice to terminate, we determined through the course of our negotiations and due diligence that a reset of some of the terms was in our shareholders’ best interests. FSD Pharma remains very interested in synthetic cannabinoid platforms and will continue to pursue accretive opportunities in this area.”
Bokhari added, “It is important to note that our efforts to gain full US exchange listing are advancing as planned. We are also in active and positive conversations with potential strategic and investment partners across the globe”.
On October 22, FSD Pharma announced the signing of the binding LOI to acquire Therapix Biosciences as part of the company’s strategic objective to develop pharmaceutical assets in the cannabinoid research space.
About FSD Pharma
FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company’s phase one growth plan involves the development of 25,000 square feet of indoor grow space at its Ontario facility and an additional 220,000 square feet, which pending approval by Health Canada, is expected to be operational in the first quarter 2019.
FSD facilities sit on 72 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer of cannabis having received its cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on October 13, 2017 and is now operating under the recently enacted Cannabis Act. FV Pharma vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting, new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.
Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. This release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
Contacts
Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.
Email:zeeshan@fsdpharma.com
Telephone: (416) 854-8884
Investor Relations
Email: IR@fsdpharma.com
Website: www.fsdpharma.com
Media Relations
Ned Berkowitz
Email: Ned.Berkowitz@russopartnersllc.com
Tel: (646) 942-5629
Zeeshan Saeed
December 22 at 4:13 PM
Want to wish everyone a very Merry Christmas and Happy Holidays!
Once again I would like to thank all our shareholders for having confidence in FSD PHARMA Inc. Without your support we would not have been able to become successful. You are our most valuable asset!!
https://www.scotiaitrade.com/en/direct-investing-and-online-trading/trading-fees/commissions-and-fees.html
I pay 9.99..regardless of how I place the trade.
It is determined by the value of your assets...not a flat fee at my broker.
Never been charged anything extra..ever.
Fact..not theory...
You think you have all the answers....lol
You seem to think so..lol
NO clue what you're going on about..I do not pay anything extra when I call in to place a trade...
9.99 regardless....
Move on...I do not view you as any kind of expert...so just don't engage with me...IC#B..now there's a great investment.
Theory or fact?
You stated it as fact.
Now you call it a theory.
I have no clue what Ziv is or isn't doing nor do you.
NO...nice try..I never said anything about Ziv..you did..What I do know for a fact is this is tax loss selling time...that is a fact..
My point is you are stating an opinion..not a fact because you can't in any way shape or form verify what you've stated.
Who says these are retail?
and btw..with my broker if I do a trade over the phone I can in fact do a 5 digit trade..have done this many times.
I cannot do it online myself.
Tax loss selling...not a theory..a fact.
Any number of shareholders could be done with OW and decided to take the hit and loss and move on.
Big mistake.
You didn't answer my question...How do you know as fact that it's Ziv?
You made a statement...back it up...
Fact is you can't prove this has anything to do with Ziv...just pure speculation.
and you know this as a fact..how?
Across the whole sector..this is not unique to OWCP as some would have you believe.
All of my mj stocks have taken a severe haircut this fall.
It appears that FSD caused this deal to fall through and not Therapix..FSD wanted to amend the original LOI....so I don't think there's 600k payable to FSD at all..they caused this to fall through...the way I'm reading it...this is from the Therapix pr... FSD proposed to modify material terms of the Transaction established by the LOI. The board of directors of the Company does not believe it will come to agreement on revised terms. Therefore, the Board has determined that it is in the best interests of the Company to terminate the LOI. Pursuant to the notice provisions of the LOI and the Company’s notice of termination, the LOI will terminate December 26, 2018.
THis is what awaits OWCP----> https://uk.finance.yahoo.com/news/cannabis-company-tilray-shares-jump-143600562.html
If you are too blind to see what is being developed at OW then I have no clue why you invested in the first place.
The only thing worse than being blind is having sight but no vision.
Helen Keller
He's an amazing man!
For those that continue to rag on the company..and anyone else(shareholders) that don't understand the significance of OWCP being an Israeli company..spend a little time and watch this video..Cannabis research started in Israel in 1965..
http://mechoulamthescientist.com/
THis is a buy and hold..not a flipper...
You need to research the company and its' plans.
Trying to flip..waste of time.
https://view.joomag.com/canadian-cannainvestor-magazine-december-2018/0045922001542631722?token=xBd7xtAGSSqOjuMAXE079L8wPK175m6PpqYBYlUVYzPd%2BDT3LMqmIszpuCMeUrdT9hjHq8Gk5I3o3O%2BCRmxcOufoolYaYGVVAmu%2BF3RhX%2B13UvzLk%2F1X%2FjnuJvXYWgxOeZiP%2FT7NRLJQitP%2BficvR0351rIUHANlNMrfY1CwFuMzQnwT07uDKSTzsF2WR7ebYtkn7%2FsIGSC9v%2FTA92n3UA%3D%3D&ref=email
Page 86---> read
If this link won't open for you register free and then you can access.
CANNAINVESTOR Magazine
Big deal..I'm from Oshawa.
Former executive(s) from GW pharma and Tweed on board!
Debt free!
No institutional money involved and 33 million in cash in the bank!
Whether you want to believe it or not FSd is poised to become a major player in the cannabis market
Hello,
Glad you have taken interest in the company. Back in July, the company responded to criticism towards it’s share structure and I recommend giving it a read. https://equity.guru/2018/07/11/audio-fsd-pharma-huge-c-director-calls-pledges-answer-tough-questions/
Our share structure is based off of Australian mining companies. Having a large float and issuing shares at a low price.
The stock breaking volume records proves we are highly liquid, despite our share count.
Best Regards,
IR